Shire and Novo are in line for exits from liver disease startup Mirum Pharmaceuticals, which has filed to raise $86.3m in its IPO.
Mirum Pharmaceuticals, a US-based liver disease therapy developer backed by pharmaceutical firms Shire and Novo, has filed for an $86.3m initial public offering on the Nasdaq Global Market.
Founded in 2018, Mirum is developing drugs to treat orphan liver diseases. Part of the IPO proceeds will fund phase 3 clinical trials for its lead product candidate, Maralixibat, in progressive familial intrahepatic cholestasis and Alagille syndrome.
The company also intends to use the cash for phase 2 trials for a second…
